Interdisziplinärer Expertenkonsensus zu Innovationen der bildgebenden Diagnostik und radionuklidbasierten Therapien des fortgeschrittenen Prostatakarzinoms
Standard
Interdisziplinärer Expertenkonsensus zu Innovationen der bildgebenden Diagnostik und radionuklidbasierten Therapien des fortgeschrittenen Prostatakarzinoms. / Beyersdorff, Dirk; Rahbar, Kambiz; Essler, Markus; Ganswindt, Ute; Grosu, Anca-Ligia; Gschwend, Jürgen E; Miller, Kurt; Scheidhauer, Klemens; Schlemmer, Heinz-Peter; Wolff, Johannes Maria; Krause, Bernd Joachim.
in: UROLOGE, Jahrgang 60, Nr. 12, 12.2021, S. 1579-1585.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Interdisziplinärer Expertenkonsensus zu Innovationen der bildgebenden Diagnostik und radionuklidbasierten Therapien des fortgeschrittenen Prostatakarzinoms
AU - Beyersdorff, Dirk
AU - Rahbar, Kambiz
AU - Essler, Markus
AU - Ganswindt, Ute
AU - Grosu, Anca-Ligia
AU - Gschwend, Jürgen E
AU - Miller, Kurt
AU - Scheidhauer, Klemens
AU - Schlemmer, Heinz-Peter
AU - Wolff, Johannes Maria
AU - Krause, Bernd Joachim
N1 - © 2021. The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - BACKGROUND: Numerous diagnostic and therapeutic innovations in the treatment of advanced prostate cancer, both in the hormone-sensitive and in the castration-resistant situation, recently led to a new orientation in the management of this tumor. However, there are potential indications beyond the ones covered by the S3 guideline on early detection, diagnosis and therapy of prostate cancer in clinical care that might be helpful for patients.OBJECTIVES: Since July 2018, an interdisciplinary group of experts from nuclear medicine, radiologists, radio-oncologists and urologists developed a consensus paper on state-of-the-art innovations in imaging diagnostics and radionuclide-based therapies for advanced prostate cancer.CONCLUSIONS: Provided by the working group are suggestions and strategies to improve the implementation of new imaging techniques such as multiparametric magnetic resonance imaging (mpMRI), PSMA-PET/CT (prostate-specific membrane antigen-positron emission tomography/computed tomography) and innovative therapeutic options (radium-223 dichloride, lutetium-177-PSMA) in the complex treatment of metastatic castration-resistant prostate cancer (mCRPC).
AB - BACKGROUND: Numerous diagnostic and therapeutic innovations in the treatment of advanced prostate cancer, both in the hormone-sensitive and in the castration-resistant situation, recently led to a new orientation in the management of this tumor. However, there are potential indications beyond the ones covered by the S3 guideline on early detection, diagnosis and therapy of prostate cancer in clinical care that might be helpful for patients.OBJECTIVES: Since July 2018, an interdisciplinary group of experts from nuclear medicine, radiologists, radio-oncologists and urologists developed a consensus paper on state-of-the-art innovations in imaging diagnostics and radionuclide-based therapies for advanced prostate cancer.CONCLUSIONS: Provided by the working group are suggestions and strategies to improve the implementation of new imaging techniques such as multiparametric magnetic resonance imaging (mpMRI), PSMA-PET/CT (prostate-specific membrane antigen-positron emission tomography/computed tomography) and innovative therapeutic options (radium-223 dichloride, lutetium-177-PSMA) in the complex treatment of metastatic castration-resistant prostate cancer (mCRPC).
KW - Consensus
KW - Humans
KW - Male
KW - Positron Emission Tomography Computed Tomography
KW - Prostatic Neoplasms/diagnostic imaging
KW - Radioisotopes
U2 - 10.1007/s00120-021-01598-2
DO - 10.1007/s00120-021-01598-2
M3 - SCORING: Review
C2 - 34406465
VL - 60
SP - 1579
EP - 1585
JO - UROLOGE
JF - UROLOGE
SN - 0340-2592
IS - 12
ER -
